MCM
KYMR icon

Manchester Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Manchester Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.56K Hold
31
– – ﹤0.01% 945
2026
Q1 		$2.58K Hold
31
– – ﹤0.01% 978
2025
Q4 		$2.41K Buy
+31
New +$2.09K ﹤0.01% 987

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Manchester Capital Management's KYMR Position: Q2 2026 in Review

Manchester Capital Management held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 31 shares worth $3.56K. The position accounts for ﹤0.01% of the portfolio, ranked #945.

Manchester Capital Management first reported a position in KYMR in Q4 2025 and has held it in 3 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Manchester Capital Management held 31 shares of Kymera Therapeutics worth $3.56K as of Q2 2026.
  • Manchester Capital Management left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of Manchester Capital Management's portfolio in Q2 2026, its #945 holding.
  • Manchester Capital Management first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.